Affinia Therapeutics Announces FDA Acceptance of IND Application to Advance AFTX-201 to a Phase 1/2 Trial for the Treatment of BAG3-Associated Dilated Cardiomyopathy (DCM)

The UPBEAT (c) clinical trial is a multicenter, open-label Phase 1/2 clinical trial designed to evaluate the safety, tolerability, pharmacodynamics, and preliminary efficacy of AFTX-201 in adults with ...
GlobalData on MSN

Affinia receives FDA approval for Phase I/II trial for dilated cardiomyopathy

Participants will each receive a single intravenous infusion of AFTX-201 at doses determined from preclinical studies.
Gigwise

The Difference Between Safety Glasses and Laser Glasses

One of the most widely used safety requirements in working environments, laboratories, workshops, and factories is eye ...
TheHealthSite

Retinoblastoma: The Most Common Eye Cancer In Children, Warning Signs Parents Must Not Ignore

Retinoblastoma is the most common eye cancer in children. Learn early warning signs, causes, diagnosis and why timely treatment can save a child’s vision and life.
Pharmabiz

Longeveron receives Japanese patent for potency assay methods to assess human mesenchymal stem cells

Longeveron receives Japanese patent for potency assay methods to assess human mesenchymal stem cells: Miami Saturday, January 31, 2026, 13:00 Hrs [IST] Longeveron Inc, a clinical ...
iMotions

Converting Raw Eye-Tracking Data into Cognitive Load Indicators

Discover how raw eye-tracking data can be transformed into effective cognitive load indicators, providing insights into how ...